FitLife Brands Sees FY24 Revenue $64M-$65M, Up 21%-23% YoY

Benzinga
03-13

FitLife Brands, Inc. ("FitLife," or the "Company") (NASDAQ:FTLF), a provider of innovative and proprietary nutritional supplements and wellness products, today announced that it will participate in the 37th Annual Roth Conference on Monday and Tuesday, March 17-18, 2025.  Investors who are interested in meeting with FitLife management should submit their requests through their Roth representative.

In conjunction with its participation in the conference, the Company has prepared an updated investor presentation which will be filed with the Securities and Exchange Commission on Form 8-K in advance of the conference. 

The Company plans to report its financial performance for the fourth quarter and full year of 2024 with the Securities and Exchange Commission on Form 10-K on March 27, 2025.  However, in order to facilitate upcoming investor discussions, the Company is providing the following financial and operational update regarding the Company's recent performance:

  • Net revenue for the full year 2024 is anticipated to be between $64-65 million, an increase of 21-23% compared to 2023.
  • Adjusted EBITDA for the full year 2024 is anticipated to be between $14.0-14.2 million, an increase of 38-40% compared to 2023.
  • Net income for the full year 2024 is anticipated to be between $8.9-9.1 million, an increase of 68-72% compared to 2023.
  • As of December 31st, 2024, the Company had $13.1 million outstanding on its term loan and no balance outstanding on its revolver.
  • As of December 31st, 2024, the Company had $4.5 million of cash.
    • Shares outstanding as of March 12, 2025 were 9,218,528.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10